Hewlett-Packard’s healthcare operations entered a new era last week with the launch of Agilent Technologies, HP’s new $8 billion technology spin-off. HP’s medical products group, along with four other businesses, were spun off by Palo
Hewlett-Packards healthcare operations entered a new era last week with the launch of Agilent Technologies, HPs new $8 billion technology spin-off. HPs medical products group, along with four other businesses, were spun off by Palo Alto, CA-based HP in a move to focus on its core computer business (SCAN 3/17/99).
In healthcare, the HP name will be continued through this years RSNA meeting, and will transition over time to the Agilent brand, according to David Kolstad, worldwide marketing manager for imaging systems. The spin-off will provide HP customers with a heightened level of speed and focus, as the healthcare solutions group will represent a much larger portion of Agilent than it did of HP, Kolstad said. Cynthia Danaher will maintain her role in the move from HP and continue to head up Agilents healthcare solutions group.
As it takes on a new identity, the Andover, MA-based unit will face the challenge of maintaining the customer loyalty and market momentum enjoyed by HP. The company earlier this year claimed to be the largest ultrasound vendor in the world, based on 1998 equipment sales and service revenues (SCAN 6/9/99). The claim was based on an independent report published by New York City research firm Klein Biomedical Consultants, which ranked HP as the number-one medical diagnostic ultrasound provider worldwide in 1998, exceeding $500 million in revenues. HP overtook Toshiba, which had historically been the market leader.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.